Revolutionizing Plasma Supply with Haemafrac®
Aegros (aegros.com.au) earns a Brand Analyzer score of 71 out of 100, placing it in the Brand-Ready tier among Healthcare brands, Technology brands. Among 2305 Healthcare brands analyzed, Aegros ranks in the 68th percentile (category average 68, leader 95). The score combines seven dimensions - name quality, digital presence, visual identity, messaging clarity, trust foundation, AI discoverability, and brand authority - into a single objective benchmark. Dimension scores: Name Quality 100/100, Digital Presence 82/100, Visual Identity 97/100, Messaging Clarity 95/100, Trust Foundation 70/100, AI Discoverability 75/100, Brand Authority 17/100.
Aegros is an Australian healthcare and technology company that has developed Haemafrac®, a proprietary plasma fractionation process designed to address global supply constraints of plasma-derived medicinal products. The company fractionates human plasma into specialty medicinal proteins, including hyperimmune globulins, at lower cost than conventional methods. Aegros positions itself as breaking a 70-year-old status quo in plasma fractionation to improve global access to life-saving medicines.
| Brand Name | Aegros |
|---|---|
| Domain | aegros.com.au |
| Industry | Healthcare, Technology |
| Founded | 1658 |
| Main Competitors | CSL Behring, Grifols, Takeda Pharmaceuticals, Octapharma, Kedrion Biopharma |
Moz Domain Authority 16/100 vs category average 29 / leader 95 - limited third-party links, so AI systems rarely encounter mentions of the brand.
No Wikipedia presence was found - a major gap, since Wikipedia is among the most heavily weighted sources in AI training data.
The homepage meta description reads "Plasma Derived Medicinal Products We solve the problem of Global Demand and Supply Constraints of Plasma, using innovation, technology and breaking a 70 year old status quo. Learn …" (No meta description. OG description present and descriptive) - this is the summary AI engines are most likely to quote.
Structured data on the homepage: 1 JSON-LD block(s), Organization schema, Breadcrumb/Website schema, + Microdata, og:title, og:description, og:image, og:type, Twitter cards, canonical. Adding FAQ schema would further help AI crawlers parse the brand's identity.
AI-crawler access: robots.txt present, no AI bot restrictions - robots.txt controls whether engines like GPTBot and ClaudeBot can read the site at all.
Social footprint: verified profiles on YouTube, LinkedIn, Instagram, GitHub; no detected presence on X (Twitter), Facebook - consistent profiles reinforce the brand's identity across the web.
0 Reddit mentions - community discussion signals real-world reputation to AI models.
Aegros scores 28/100 for AI visibility - how well ChatGPT, Claude, Perplexity and Google AI Overviews can discover, identify and cite the brand.
Aegros has a weak AI-visibility profile at 28/100 - a proxy for how readily ChatGPT, Perplexity and Google's AI Overviews can recognise and cite it. Its strongest area is recommendation likelihood (45/100) and its weakest is visibility (13/100). It benefits from a Wikidata knowledge-graph entry, open access for AI crawlers (GPTBot, ClaudeBot, etc.) and machine-readable schema.org markup. The main gaps holding it back: no clear Wikipedia entity to anchor it in LLM training data, a low Moz Domain Authority of 16/100 and no llms.txt to steer AI to its best pages.
Common questions people ask in Google, ChatGPT, Claude, Gemini, Perplexity, and other AI search engines.
Aegros's main competitors include CSL Behring, Grifols, Takeda Pharmaceuticals, Octapharma, Kedrion Biopharma. These companies compete in the Healthcare space for similar customers, offering comparable products or services.
Sources: Aegros official site
Popular alternatives to Aegros include CSL Behring, Grifols, Takeda Pharmaceuticals, Octapharma, Kedrion Biopharma. Each is an established option in the Healthcare space; the best fit depends on your specific needs, budget, and required features.
Sources: Aegros official site
Aegros has limited AI-search visibility, scoring 28/100 on Brand Analyzer's AI visibility composite (visibility 13, trust 36, recommendation 45). This estimates how likely AI engines like ChatGPT, Claude, Gemini and Perplexity are to know, trust, and recommend the brand.
Sources: Aegros official site
Aegros was founded in 1658. Aegros operates in the Healthcare category. It is analyzed by Brand Analyzer across seven brand dimensions and AI-search visibility.
Sources: Wikidata
Aegros offers plasma fractionation technology and services centered on its proprietary Haemafrac® process. Through this process, the company produces plasma-derived medicinal proteins, specifically noted to include hyperimmune globulins. These are described as high-purity specialty biological medicines intended to address chronic global shortages of plasma-derived therapies. The company operates in the plasma-derived medicinal products category within the broader healthcare and biotechnology sectors.
Sources: Aegros official site
Aegros fractionates human plasma into specialty medicinal proteins using its proprietary Haemafrac® process. This process is described as unique and transformational, producing high-purity specialty proteins such as hyperimmune globulins at lower cost than conventional methods. The company's stated goal is to address chronic global shortages of plasma-derived, life-saving medicines by offering a more efficient and accessible fractionation technology.
Sources: Aegros official site
Aegros is an Australian healthcare and technology company operating in the plasma-derived medicinal products sector. It has developed a proprietary technology called Haemafrac® that fractionates human plasma into specialty medicinal proteins. The company describes itself as solving global demand and supply constraints of plasma through innovation and technology, and positions itself as breaking a 70-year-old status quo in the plasma fractionation industry.
Sources: Aegros official site
Aegros and CSL Behring are competitors in Healthcare. They target overlapping audiences; the right choice depends on your specific needs and priorities.
Sources: Aegros official site
Aegros scores 45/100 on Brand Analyzer's AI recommendation signal, indicating it is less likely to be surfaced when AI assistants like ChatGPT suggest Healthcare options. Recommendation depends on crawlability, structured data, and category authority.
Sources: Aegros official site
Aegros is known for inventing the Haemafrac® plasma fractionation process, which the company describes as a revolutionary approach to producing plasma-derived medicinal proteins. It is recognized for challenging the conventional plasma fractionation model that has remained largely unchanged for approximately 70 years, and for its focus on addressing global supply shortages of life-saving plasma-derived therapies.
Sources: Aegros official site
Aegros can improve AI discoverability by strengthening structured data (Organization and FAQ schema), maintaining an accurate Wikipedia/Wikidata entity, earning authoritative citations, and keeping content crawlable for AI bots. Brand Analyzer measures these as visibility, trust, and recommendation signals.
Sources: Aegros official site
According to available information, Aegros's target audience includes patients who require plasma-derived medicines, healthcare providers who administer such therapies, and global pharmaceutical markets that face ongoing plasma shortages. The company's products and technology are directed at addressing supply constraints that affect patients and healthcare systems worldwide who depend on specialty plasma-derived proteins for treatment.
Sources: Aegros official site
Ranked closest to Aegros: Aaniie (71/100), ZONTAL (72/100), AFRIpads (71/100), AgileBrain (71/100).
A step up - brands to learn from: Zipline (81/100), Zimmer Biomet (81/100).
Category leader: Dassault Systèmes (95/100).